Cargando…

Comparative Evaluation of Vitek 2 and Etest versus Broth Microdilution for Ceftazidime/Avibactam and Ceftolozane/Tazobactam Susceptibility Testing of Enterobacterales and Pseudomonas aeruginosa

Ceftazidime/avibactam (CZA) and ceftolozane/tazobactam (C/T) are novel antibiotics with activity against multidrug-resistant Gram-negative pathogens. Nevertheless, resistance to both agents has been reported emphasizing the need for accurate and widely accessible susceptibility testing. In the prese...

Descripción completa

Detalles Bibliográficos
Autores principales: Papadomanolaki, Arhodoula, Siopi, Maria, Karakosta, Polyxeni, Vourli, Sophia, Pournaras, Spyros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9312067/
https://www.ncbi.nlm.nih.gov/pubmed/35884118
http://dx.doi.org/10.3390/antibiotics11070865
_version_ 1784753752693014528
author Papadomanolaki, Arhodoula
Siopi, Maria
Karakosta, Polyxeni
Vourli, Sophia
Pournaras, Spyros
author_facet Papadomanolaki, Arhodoula
Siopi, Maria
Karakosta, Polyxeni
Vourli, Sophia
Pournaras, Spyros
author_sort Papadomanolaki, Arhodoula
collection PubMed
description Ceftazidime/avibactam (CZA) and ceftolozane/tazobactam (C/T) are novel antibiotics with activity against multidrug-resistant Gram-negative pathogens. Nevertheless, resistance to both agents has been reported emphasizing the need for accurate and widely accessible susceptibility testing. In the present study, Vitek 2 and Etest CAZ and C/T MIC results for 100 non-repetitive clinical isolates (83 Enterobacterales and 17 P. aeruginosa, whereof 69 challenge isolates) were compared to the standard broth microdilution (BMD) method. EUCAST breakpoints were used for assessing the categorical (CA) and essential (EA) agreement between the methods along with the corresponding error rates. The Vitek 2 performance was comparable to that of BMD for testing both antimicrobial agents exceeding the ISO requirements (CA 98–99%, EA 96–100%, major errors (MEs) 0–1%, very major error (VMEs) 1%). Likewise, the Etest provided accurate results for CZA and C/T testing against Enterobacterales and P. aeruginosa, respectively (CA 100%, EA 97–100%, MEs 0%, VMEs 0%). On the contrary, EA of 85% and 6% VME rate were found for CZA Etest and P. aeruginosa. Overall, Vitek 2 measurements of CZA and C/T susceptibility correlated closely with the reference BMD, indicating that it can represent a suitable alternative to BMD for susceptibility testing of Enterobacterales and P. aeruginosa. The Etest did not fulfill the ISO performance criteria of EA and VME for CZA and P. aeruginosa. Further studies are needed to assess whether the Etest allows a reliable assessment of CZA and C/T EUCAST MICs.
format Online
Article
Text
id pubmed-9312067
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93120672022-07-26 Comparative Evaluation of Vitek 2 and Etest versus Broth Microdilution for Ceftazidime/Avibactam and Ceftolozane/Tazobactam Susceptibility Testing of Enterobacterales and Pseudomonas aeruginosa Papadomanolaki, Arhodoula Siopi, Maria Karakosta, Polyxeni Vourli, Sophia Pournaras, Spyros Antibiotics (Basel) Article Ceftazidime/avibactam (CZA) and ceftolozane/tazobactam (C/T) are novel antibiotics with activity against multidrug-resistant Gram-negative pathogens. Nevertheless, resistance to both agents has been reported emphasizing the need for accurate and widely accessible susceptibility testing. In the present study, Vitek 2 and Etest CAZ and C/T MIC results for 100 non-repetitive clinical isolates (83 Enterobacterales and 17 P. aeruginosa, whereof 69 challenge isolates) were compared to the standard broth microdilution (BMD) method. EUCAST breakpoints were used for assessing the categorical (CA) and essential (EA) agreement between the methods along with the corresponding error rates. The Vitek 2 performance was comparable to that of BMD for testing both antimicrobial agents exceeding the ISO requirements (CA 98–99%, EA 96–100%, major errors (MEs) 0–1%, very major error (VMEs) 1%). Likewise, the Etest provided accurate results for CZA and C/T testing against Enterobacterales and P. aeruginosa, respectively (CA 100%, EA 97–100%, MEs 0%, VMEs 0%). On the contrary, EA of 85% and 6% VME rate were found for CZA Etest and P. aeruginosa. Overall, Vitek 2 measurements of CZA and C/T susceptibility correlated closely with the reference BMD, indicating that it can represent a suitable alternative to BMD for susceptibility testing of Enterobacterales and P. aeruginosa. The Etest did not fulfill the ISO performance criteria of EA and VME for CZA and P. aeruginosa. Further studies are needed to assess whether the Etest allows a reliable assessment of CZA and C/T EUCAST MICs. MDPI 2022-06-27 /pmc/articles/PMC9312067/ /pubmed/35884118 http://dx.doi.org/10.3390/antibiotics11070865 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Papadomanolaki, Arhodoula
Siopi, Maria
Karakosta, Polyxeni
Vourli, Sophia
Pournaras, Spyros
Comparative Evaluation of Vitek 2 and Etest versus Broth Microdilution for Ceftazidime/Avibactam and Ceftolozane/Tazobactam Susceptibility Testing of Enterobacterales and Pseudomonas aeruginosa
title Comparative Evaluation of Vitek 2 and Etest versus Broth Microdilution for Ceftazidime/Avibactam and Ceftolozane/Tazobactam Susceptibility Testing of Enterobacterales and Pseudomonas aeruginosa
title_full Comparative Evaluation of Vitek 2 and Etest versus Broth Microdilution for Ceftazidime/Avibactam and Ceftolozane/Tazobactam Susceptibility Testing of Enterobacterales and Pseudomonas aeruginosa
title_fullStr Comparative Evaluation of Vitek 2 and Etest versus Broth Microdilution for Ceftazidime/Avibactam and Ceftolozane/Tazobactam Susceptibility Testing of Enterobacterales and Pseudomonas aeruginosa
title_full_unstemmed Comparative Evaluation of Vitek 2 and Etest versus Broth Microdilution for Ceftazidime/Avibactam and Ceftolozane/Tazobactam Susceptibility Testing of Enterobacterales and Pseudomonas aeruginosa
title_short Comparative Evaluation of Vitek 2 and Etest versus Broth Microdilution for Ceftazidime/Avibactam and Ceftolozane/Tazobactam Susceptibility Testing of Enterobacterales and Pseudomonas aeruginosa
title_sort comparative evaluation of vitek 2 and etest versus broth microdilution for ceftazidime/avibactam and ceftolozane/tazobactam susceptibility testing of enterobacterales and pseudomonas aeruginosa
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9312067/
https://www.ncbi.nlm.nih.gov/pubmed/35884118
http://dx.doi.org/10.3390/antibiotics11070865
work_keys_str_mv AT papadomanolakiarhodoula comparativeevaluationofvitek2andetestversusbrothmicrodilutionforceftazidimeavibactamandceftolozanetazobactamsusceptibilitytestingofenterobacteralesandpseudomonasaeruginosa
AT siopimaria comparativeevaluationofvitek2andetestversusbrothmicrodilutionforceftazidimeavibactamandceftolozanetazobactamsusceptibilitytestingofenterobacteralesandpseudomonasaeruginosa
AT karakostapolyxeni comparativeevaluationofvitek2andetestversusbrothmicrodilutionforceftazidimeavibactamandceftolozanetazobactamsusceptibilitytestingofenterobacteralesandpseudomonasaeruginosa
AT vourlisophia comparativeevaluationofvitek2andetestversusbrothmicrodilutionforceftazidimeavibactamandceftolozanetazobactamsusceptibilitytestingofenterobacteralesandpseudomonasaeruginosa
AT pournarasspyros comparativeevaluationofvitek2andetestversusbrothmicrodilutionforceftazidimeavibactamandceftolozanetazobactamsusceptibilitytestingofenterobacteralesandpseudomonasaeruginosa